サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1459812

腫瘍溶解性ウイルス免疫療法市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Oncolytic Virus Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 182 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
腫瘍溶解性ウイルス免疫療法市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年
出版日: 2024年02月09日
発行: Transparency Market Research
ページ情報: 英文 182 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

腫瘍溶解性ウイルス免疫療法市場- 調査範囲

TMR社の調査レポート「世界の腫瘍溶解性ウイルス免疫療法市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2023年を基準年、2031年を予測年として、2017年から2031年までの世界の腫瘍溶解性ウイルス免疫療法市場の収益と予測を提供します。また、2023年から2031年までの世界の腫瘍溶解性ウイルス免疫療法市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、腫瘍溶解性ウイルス免疫療法市場を理解しました。

市場スナップショット
2022年の市場価値 1億1,020万米ドル
2031年の市場価値 5億7,220万米ドル
CAGR 21.1%

本レポートでは、世界の腫瘍溶解性ウイルス免疫療法市場の競合情勢について調査しています。世界の腫瘍溶解性ウイルス免疫療法市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の腫瘍溶解性ウイルス免疫療法市場のプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場分析と予測、2017年～2031年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：タイプ別、2017年～2031年
    • 単純ヘルペスウイルス
    • ワクチンウイルス
    • アデノウイルス
    • レオウイルス
    • その他
  • 市場魅力度分析：タイプ別

第7章 世界市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2017年～2031年
    • 腫瘍内
    • 静脈内
  • 市場魅力度分析：投与経路別

第8章 世界市場分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：用途別、2017年～2031年
    • メラノーマ
    • 非小細胞肺がん（NSCLC）
    • 膵臓がん
    • 乳がん
    • その他
  • 市場魅力度分析：投与経路別

第9章 世界市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場分析と予測

第11章 欧州市場分析と予測

第12章 アジア太平洋市場分析と予測

第13章 ラテンアメリカ市場分析と予測

第14章 中東・アフリカ市場分析と予測

第15章 競合情勢

  • 市場競合マトリックス（ティア別、企業規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • Amgen Inc.
    • Merck & Co., Inc.（Viralytics Limited）
    • Shanghai Sunway Biotech Co., Ltd.
    • TILT Biotherapeutics
    • Oncorus, Inc.
    • Replimune Group, Inc.
    • Oncolys Biopharma, Inc.
    • Sorrento Therapeutics, Inc.
    • Oncolytics Biotech, Inc.
    • SillaJen, Inc.
図表

List of Tables

  • Table 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 02: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 03: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 04: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 07: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 08: North America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 09: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 11: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 12: Europe Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 13: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 15: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 16: Asia Pacific Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 17: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 19: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 20: Latin America Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031
  • Table 21: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Type, 2017-2031
  • Table 23: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2031
  • Table 24: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast, by Application, 2017-2031

List of Figures

  • Figure 01: Global Oncolytic Virus Immunotherapy Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Type, 2022
  • Figure 03: Global Oncolytic Virus Immunotherapy Market Value Share, by Type, 2022
  • Figure 04: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Route of Administration, 2022
  • Figure 05: Global Oncolytic Virus Immunotherapy Market Value Share, by Route of Administration, 2022
  • Figure 06: Global Oncolytic Virus Immunotherapy Market Revenue (US$ Mn), by Application, 2022
  • Figure 07: Global Oncolytic Virus Immunotherapy Market Value Share, by Application, 2022
  • Figure 08: Global Oncolytic Virus Immunotherapy Market Value Share, by Region, 2022
  • Figure 09: Global Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 11: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 12: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 13: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 14: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 15: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 16: Global Oncolytic Virus Immunotherapy Market Value Share Analysis, by Region, 2022-2031
  • Figure 17: Global Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country, 2022-2031
  • Figure 21: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 22: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 23: North America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 24: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 25: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 26: North America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 27: Europe Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 31: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 32: Europe Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 33: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 34: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 35: Europe Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 36: Asia Pacific Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 39: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 40: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 41: Asia Pacific Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 42: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 43: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 44: Asia Pacific Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 45: Latin America Oncolytic Virus Immunotherapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 48: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 49: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 50: Latin America Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 51: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 52: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 53: Latin America Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
  • Figure 54: Middle East & Africa Oncolytic Virus Immunotherapy Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Type, 2022-2031
  • Figure 58: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Route of Administration, 2022-2031
  • Figure 59: Middle East & Africa Oncolytic Virus Immunotherapy Market Value Share Analysis, by Application, 2022-2031
  • Figure 60: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Type, 2023-2031
  • Figure 61: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Route of Administration, 2023-2031
  • Figure 62: Middle East & Africa Oncolytic Virus Immunotherapy Market Attractiveness Analysis, by Application, 2023-2031
目次
Product Code: TMRGL44931

Oncolytic Virus Immunotherapy Market - Scope of Report

TMR's report on the global oncolytic virus immunotherapy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global oncolytic virus immunotherapy market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global oncolytic virus immunotherapy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the oncolytic virus immunotherapy market.

Market Snapshot
Market Value in 2022US$ 110.2 Mn
Market Value in 2031US$ 572.2 Mn
CAGR21.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global oncolytic virus immunotherapy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global oncolytic virus immunotherapy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global oncolytic virus immunotherapy market.

The report delves into the competitive landscape of the global oncolytic virus immunotherapy market. Key players operating in the global oncolytic virus immunotherapy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global oncolytic virus immunotherapy market profiled in this report.

Key Questions Answered in Global oncolytic virus immunotherapy Market Report:

  • What is the sales/revenue generated by oncolytic virus immunotherapy across all regions during the forecast period?
  • What are the opportunities in the global oncolytic virus immunotherapy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Oncolytic Virus Immunotherapy Market - Research Objectives and Research Approach

The comprehensive report on the global oncolytic virus immunotherapy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global oncolytic virus immunotherapy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global oncolytic virus immunotherapy market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Oncolytic Virus Immunotherapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Type, 2017-2031
    • 6.3.1. Herpes Simplex Virus
    • 6.3.2. Vaccinia Virus
    • 6.3.3. Adenovirus
    • 6.3.4. Reovirus
    • 6.3.5. Others
  • 6.4. Market Attractiveness Analysis, by Type

7. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Route of Administration, 2017-2031
    • 7.3.1. Intratumoral
    • 7.3.2. Intravenous
  • 7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Application, 2017-2031
    • 8.3.1. Melanoma
    • 8.3.2. Non-small Cell Lung Cancer (NSCLC)
    • 8.3.3. Pancreatic Cancer
    • 8.3.4. Breast Cancer
    • 8.3.5. Others
  • 8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Oncolytic Virus Immunotherapy Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Type, 2017-2031
    • 10.3.1. Herpes Simplex Virus
    • 10.3.2. Vaccinia Virus
    • 10.3.3. Adenovirus
    • 10.3.4. Reovirus
    • 10.3.5. Others
  • 10.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 10.4.1. Intratumoral
    • 10.4.2. Intravenous
  • 10.5. Market Value Forecast, by Application, 2017-2031
    • 10.5.1. Melanoma
    • 10.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 10.5.3. Pancreatic Cancer
    • 10.5.4. Breast Cancer
    • 10.5.5. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Type
    • 10.7.2. By Route of Administration
    • 10.7.3. By Application
    • 10.7.4. By Country

11. Europe Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Type, 2017-2031
    • 11.3.1. Herpes Simplex Virus
    • 11.3.2. Vaccinia Virus
    • 11.3.3. Adenovirus
    • 11.3.4. Reovirus
    • 11.3.5. Others
  • 11.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 11.4.1. Intratumoral
    • 11.4.2. Intravenous
  • 11.5. Market Value Forecast, by Application, 2017-2031
    • 11.5.1. Melanoma
    • 11.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 11.5.3. Pancreatic Cancer
    • 11.5.4. Breast Cancer
    • 11.5.5. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Type, 2017-2031
    • 12.3.1. Herpes Simplex Virus
    • 12.3.2. Vaccinia Virus
    • 12.3.3. Adenovirus
    • 12.3.4. Reovirus
    • 12.3.5. Others
  • 12.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 12.4.1. Intratumoral
    • 12.4.2. Intravenous
  • 12.5. Market Value Forecast, by Application, 2017-2031
    • 12.5.1. Melanoma
    • 12.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 12.5.3. Pancreatic Cancer
    • 12.5.4. Breast Cancer
    • 12.5.5. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By Country/Sub-region

13. Latin America Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Type, 2017-2031
    • 13.3.1. Herpes Simplex Virus
    • 13.3.2. Vaccinia Virus
    • 13.3.3. Adenovirus
    • 13.3.4. Reovirus
    • 13.3.5. Others
  • 13.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 13.4.1. Intratumoral
    • 13.4.2. Intravenous
  • 13.5. Market Value Forecast, by Application, 2017-2031
    • 13.5.1. Melanoma
    • 13.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 13.5.3. Pancreatic Cancer
    • 13.5.4. Breast Cancer
    • 13.5.5. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Oncolytic Virus Immunotherapy Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Type, 2017-2031
    • 14.3.1. Herpes Simplex Virus
    • 14.3.2. Vaccinia Virus
    • 14.3.3. Adenovirus
    • 14.3.4. Reovirus
    • 14.3.5. Others
  • 14.4. Market Value Forecast, by Route of Administration, 2017-2031
    • 14.4.1. Intratumoral
    • 14.4.2. Intravenous
  • 14.5. Market Value Forecast, by Application, 2017-2031
    • 14.5.1. Melanoma
    • 14.5.2. Non-small Cell Lung Cancer (NSCLC)
    • 14.5.3. Pancreatic Cancer
    • 14.5.4. Breast Cancer
    • 14.5.5. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. Amgen Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Merck & Co., Inc. (Viralytics Limited)
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Shanghai Sunway Biotech Co., Ltd.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. TILT Biotherapeutics
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Oncorus, Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Replimune Group, Inc.
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Oncolys Biopharma, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Sorrento Therapeutics, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Oncolytics Biotech, Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. SillaJen, Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview